Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma

Leuk Lymphoma. 2007 Aug;48(8):1630-2. doi: 10.1080/10428190701457949.
No abstract available

Publication types

  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20 / metabolism
  • Antineoplastic Agents / therapeutic use*
  • Bone Neoplasms / drug therapy
  • Female
  • Humans
  • Lung Neoplasms / drug therapy
  • Lymphoma / drug therapy*
  • Male
  • Middle Aged
  • Muscle Neoplasms / drug therapy
  • Rituximab
  • Splenic Neoplasms / drug therapy
  • Stomach Neoplasms / drug therapy
  • Survival Rate
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antigens, CD20
  • Antineoplastic Agents
  • Rituximab